- Also known as
- Tirz · LY3298176 · GIP/GLP-1 dual agonist
- Class
- GIP and GLP-1 receptor agonist
- Form
- Lyophilised powder in 20 mg and 40 mg vials
- Sizes
- 20 mg · 40 mg
- Storage, dry
- −20 °C, dry and dark
- Storage, mixed
- 2–8 °C, use within 28 days of mixing (as generally reported for reconstituted peptides)
- BAC water per size
- 20 mg: 3 mL · 40 mg: 3 mL
What is Tirzepatide?
The literature describes Tirzepatide as GIP and GLP-1 receptor agonist. Published work on it is in human. The name covers the same material written several ways in the literature, including Tirz, LY3298176 and GIP/GLP-1 dual agonist. Its sequence is recorded as Single long-acting peptide with activity at the GIP and GLP-1 receptors.. 8 of the 8 studies listed below are controlled trials in people. We hold it as lyophilised powder in 20 mg and 40 mg vials; it is research material and nothing else. It is not a drug, and it is not supplied for use in a person or an animal.
What the research shows
| Study | Model | Dose used | Duration | Finding |
|---|---|---|---|---|
| Jastreboff AM et al.2022 · N Engl J Med · PMID 35658024 | Human, phase 3 randomised controlled trial in adults with obesity, without diabetes (n=2539) — SURMOUNT-1 | 5, 10 or 15 mg once weekly, subcutaneous, vs placebo | 72 weeks, including a 20-week dose-escalation period | Mean weight change at week 72 was −15.0% (5 mg), −19.5% (10 mg) and −20.9% (15 mg) vs −3.1% with placebo. Adverse events, mostly gastrointestinal, led to discontinuation in 4.3% to 7.1% on tirzepatide vs 2.6% on placebo. |
| Jastreboff AM et al.2025 · N Engl J Med · PMID 39536238 | Human, phase 3 randomised controlled trial, obesity with prediabetes (n=1032 of 2539) — SURMOUNT-1, 3-year analysis | 5, 10 or 15 mg once weekly, vs placebo | 176 weeks, then 17 weeks off treatment | Weight change at 176 weeks was −12.3% to −19.7% vs −1.3% with placebo, and type 2 diabetes was diagnosed in 1.3% vs 13.3% (hazard ratio 0.07). No new safety signals were identified. |
| Rosenstock J et al.2021 · Lancet · PMID 34186022 | Human, phase 3 randomised controlled trial in type 2 diabetes on diet and exercise alone (n=478) — SURPASS-1 | 5, 10 or 15 mg once weekly, vs placebo | 40 weeks | HbA1c fell by 1.87%, 1.89% and 2.07% with 5, 10 and 15 mg vs a rise of 0.04% with placebo. An HbA1c below 7.0% was reached by 87–92% on tirzepatide vs 20% on placebo. |
| Frías JP et al.2021 · N Engl J Med · PMID 34170647 | Human, phase 3 open-label randomised trial vs semaglutide 1 mg in type 2 diabetes (n=1879) — SURPASS-2 | 5, 10 or 15 mg once weekly, vs semaglutide 1 mg once weekly | 40 weeks | HbA1c fell by 2.01 to 2.30 percentage points with tirzepatide vs 1.86 with semaglutide, and weight loss was 1.9 to 5.5 kg greater. Nausea was reported by 17–22% on tirzepatide and 18% on semaglutide. |
| Aronne LJ et al.2024 · JAMA · PMID 38078870 | Human, phase 3 randomised withdrawal trial in obesity, without diabetes (n=670 randomised) — SURMOUNT-4 | Maximum tolerated dose of 10 or 15 mg once weekly, subcutaneous, then continued or switched to placebo | 36-week open-label lead-in plus 52 weeks double-blind | After a mean 20.9% reduction in the lead-in, weight changed by −5.5% with continued tirzepatide vs +14.0% after switching to placebo from week 36 to 88. Withdrawal led to substantial regain of lost weight. |
| Malhotra A et al.2024 · N Engl J Med · PMID 38912654 | Human, two phase 3 randomised controlled trials in moderate-to-severe obstructive sleep apnoea with obesity — SURMOUNT-OSA | Maximum tolerated dose of 10 or 15 mg, vs placebo | 52 weeks | The apnoea-hypopnoea index fell by 25.3 and 29.3 events per hour with tirzepatide vs 5.3 and 5.5 with placebo in the two trials. Adverse events were mostly gastrointestinal and mild to moderate. |
| Packer M et al.2025 · N Engl J Med · PMID 39555826 | Human, randomised controlled trial in heart failure with preserved ejection fraction and obesity (n=731) — SUMMIT | Up to 15 mg once weekly, subcutaneous, vs placebo | At least 52 weeks (median follow-up 104 weeks) | Cardiovascular death or worsening heart failure occurred in 9.9% on tirzepatide vs 15.3% on placebo (hazard ratio 0.62). Adverse events leading to discontinuation were 6.3% vs 1.4%. |
| Loomba R et al.2024 · N Engl J Med · PMID 38856224 | Human, phase 2 randomised controlled trial in biopsy-confirmed MASH with F2–F3 fibrosis (n=190) — SYNERGY-NASH | 5, 10 or 15 mg once weekly, subcutaneous, vs placebo | 52 weeks | Resolution of MASH without worsening of fibrosis was seen in 44%, 56% and 62% on 5, 10 and 15 mg vs 10% on placebo. The authors state that larger and longer trials are needed. |
What these studies don't show: Controlled human data exists, but it is limited in scope. Selected groups and surrogate endpoints limit how far these findings reach. None of it establishes safety outside the conditions each trial ran under. Purity data confirms what is in the vial and says nothing about whether a compound works.
Every study links to its PubMed record. See all Tirzepatide studies in the research library →
Tirzepatide price in Canada: 20mg and 40mg vials
Buy Tirzepatide in Canada in 2 vial sizes and a starter kit. Prices are in Canadian dollars, you pay by Interac e-Transfer or bank transfer, and orders are shipped from Canadian stock.
| Size | Price | Per mg |
|---|---|---|
| 20 mg | $77.50 | $3.88/mg |
| 40 mg | $87.00 | $2.17/mg |
Starter kit
Is Tirzepatide available in Canada?
Tirzepatide is an authorized prescription medicine in Canada. Authorized in Canada as MOUNJARO (Eli Lilly Canada), DIN 02532921 and the KwikPen presentations. That authorization covers the licensed product, not research material, and Borealis Peptides supplies this for laboratory work only. How Health Canada treats research peptides →
Side effects reported in studies
The studies cited below report what they observed on tolerability, and those statements are reproduced as written. Human work of this size does not establish a safety profile.
Tirzepatide FAQ
What is Tirzepatide?
Suppliers and the literature both list Tirzepatide as a GIP and GLP-1 receptor agonist. The published work on it is in human. Borealis Peptides supplies it as lyophilised powder in 20 mg and 40 mg vials for in-vitro laboratory research. It is not authorized as a medicine and is not for use in any living subject. The table on this page gives each study, its model and its reported result.
Where can I buy Tirzepatide in Canada?
Direct from Borealis Peptides, held in Canadian stock so nothing crosses a border on its way to you. Stocked in 20 mg and 40 mg vials. Purity is confirmed by HPLC batch by batch, and we supply for laboratory research only.
Is Tirzepatide legal in Canada?
Tirzepatide is an authorized prescription medicine in Canada. Authorized in Canada as MOUNJARO (Eli Lilly Canada), DIN 02532921 and the KwikPen presentations. That authorization covers the licensed product, not research material, and Borealis Peptides supplies this for laboratory work only. Health Canada has said that "Research Use Only" labelling does not make a product legal to use in a person, so we treat it as a description of what the material is supplied for rather than a permission. Lawful use in your own setting is yours to establish.
How much Tirzepatide should I use?
We do not answer dosing questions. Tirzepatide is not supplied for use in a person or an animal, so there is no dose to describe. What this page carries is the amount each cited study used and the model it used it in, reproduced as the authors published it.
What human evidence is there for Tirzepatide?
Of the 8 studies cited, 8 are controlled trials in people and the rest are animal or cell work. Each row names its model, the amount used and what the authors reported, so the weight of each study can be judged directly rather than through a summary.
How long does Tirzepatide keep?
Hold sealed vials at −20 °C, dry and dark. In solution it is kept at 2–8 °C. It travels at room temperature as a dry powder and goes cold on arrival. Keeping it dark and at a steady temperature matters more than how fast it arrived.
How is the purity of Tirzepatide confirmed?
Every batch is tested by HPLC before it is sold, and the certificate refers to the batch in your vial rather than to the product in general. Keeping that batch number with your records is what makes an observation reproducible later. Certificates are available on request.
How does Tirzepatide compare with Retatrutide and Cagrilintide?
These are separate compounds with separate literatures; no ranking is offered here. Retatrutide and Cagrilintide have 6 cited studies and 8 cited studies on their page against 8 here. The useful comparison is between the two study tables and the models behind them.
Compare with
Related compounds
Cagrilintide
Long-acting amylin analogue (amylin receptor agonist)
Add 2 more to save 4%
AOD-9604
Modified C-terminal fragment of human growth hormone
Add 2 more to save 4%
SLU-PP-332
Synthetic pan-ERR (ERRα/β/γ) agonist, small molecule
Add 2 more to save 4%